Ubiquitin-specific protease 15 contributes to gastric cancer progression by regulating the Wnt/β-catenin signaling pathway
Min Zhong, Ling Zhou, Zhi Fang, Jian-Ping Zou, Jun Deng, Department of Jiangxi Key Laboratory for Individualized Cancer Therapy, The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China
Yang-Yang Yao, Jian-Ping Xiong, Xiao-Jun Xiang, Department of Cancer Center, The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China
Author contributions: Zhong M, Zhou L, and Fang Z contributed equally to this work; Zhong M performed data acquisition and drafted the manuscript; Zhou L and Fang Z completed the statistical analyses; Yao YY and Zou JP were involved in critically revising the manuscript for important intellectual content; Deng J, Xiong JP, and Xiang XJ conceived and designed the study.
Supported by National Natural Science Foundation of China, No. 81760432; Science and Technology Department of Jiangxi Province, No. 20202BBGL73036; and Jiangxi Provincial Outstanding Young Talents Projects, No. 20204BCJ23016.
Institutional review board statement: The study was reviewed and approved by the Medical Research Ethics Committee of the First Affiliated Hospital of Nanchang University.
Institutional animal care and use committee statement: All animal experiments conformed to the internationally accepted principles for the care and use of laboratory animals [license No. SYXK (GAN) 2015-0001, Laboratory Animal Science Center of Nanchang University; protocol No. 2020-130, The Medical Research Ethics Committee of the First Affiliated Hospital of Nanchang University].
Conflict-of-interest statement: The authors declare that they have no conflict of interest
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jun Deng, PhD, Assistant Professor, Department of Jiangxi Key Laboratory for Individualized Cancer Therapy, The First Affiliated Hospital of Nanchang University, No. 17 Yongwai Street, Nanchang 330006, Jiangxi Province, China. firstname.lastname@example.org
Received: March 8, 2021
Peer-review started: March 8, 2021
First decision: April 17, 2021
Revised: April 27, 2021
Accepted: June 16, 2021
Article in press: June 16, 2021
Published online: July 14, 2021